Fosamax and Osteonecrosis of the Jaw: What Are Bisphosphonate Drugs?

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy of General Health and Science Communication on Bisphosphonates

For decades, general health and science communication has served as a foundational pillar for public understanding of medical treatments. Within this legacy, the discussion of bisphosphonate drugs—commonly prescribed for conditions such as osteoporosis and certain bone diseases—has typically centered on their therapeutic benefits in managing bone density and reducing fracture risk. This broad educational context has provided patients and healthcare providers with essential knowledge about medication adherence, side effect profiles, and the importance of monitoring long-term therapy. As this informational framework evolves, a more focused area of concern has emerged: the occupational exposure risk associated with bisphosphonate use. Specifically, the drug Fosamax (alendronate) has been linked to a rare but serious condition known as osteonecrosis of the jaw (ONJ). While initial public health messaging emphasized patient-level risks during dental procedures, recent attention has shifted toward professionals who may encounter these compounds in clinical or manufacturing settings. This pivot from general health education to occupational hazard awareness reflects a growing recognition that exposure pathways extend beyond the patient's pill bottle. The transition from legacy health science to this targeted risk assessment underscores the need for updated protocols and heightened vigilance among those who handle, administer, or manufacture bisphosphonate drugs.

Bridging to Clinical Evidence: Fosamax and Osteonecrosis of the Jaw

Building on the legacy of general health communication, it is now critical to examine the specific clinical evidence linking Fosamax to osteonecrosis of the jaw (ONJ). Fosamax (alendronate) is a bisphosphonate drug approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Bisphosphonates are bone resorption inhibitors commonly used to manage osteoporosis, but they are associated with a known adverse effect: osteonecrosis of the jaw (ONJ) (https://pubmed.ncbi.nlm.nih.gov/40434545/). This condition, now classified as medication-related osteonecrosis of the jaw (MRONJ), is marked by osteonecrosis of the jaw bone and other symptoms that can significantly compromise a patient's activities of daily living (https://pubmed.ncbi.nlm.nih.gov/40434545/). The terminology has evolved from 'bisphosphonate-related osteonecrosis of the jaw' (BRONJ) to MRONJ to reflect similar phenotypes caused by other antiresorptive or anti-angiogenic therapies (https://pubmed.ncbi.nlm.nih.gov/41488140/).

Risk Factors and Clinical Presentation of ONJ

The clinical presentation of ONJ can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Although not confirmed, it is generally believed that MRONJ risk is higher with injectable rather than oral formulations (https://pubmed.ncbi.nlm.nih.gov/40434545/). Zoledronic acid, in particular, is widely used and may be administered as an annual intravenous infusion (https://pubmed.ncbi.nlm.nih.gov/41488140/).

Mechanisms and Management of Bisphosphonate-Related ONJ

The mechanistic pathways linking Fosamax to ONJ are not clearly understood (https://pubmed.ncbi.nlm.nih.gov/40434545/). Bisphosphonates with high bone-resorption capacity promote ONJ development after tooth extraction in mice, suggesting a role for bone turnover inhibition in pathogenesis (https://pubmed.ncbi.nlm.nih.gov/40434545/). Despite their therapeutic benefits, bisphosphonates are associated with both short-term and long-term adverse effects (https://pubmed.ncbi.nlm.nih.gov/41488140/). Regarding the adequacy of warnings, the prescribing information for Fosamax includes a section on osteonecrosis of the jaw, noting that it has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also states that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Current guidelines emphasize dental evaluation prior to initiation of high-potency antiresorptives (https://pubmed.ncbi.nlm.nih.gov/41488140/). However, the optimal duration of bisphosphonate use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Timeline of Symptoms and Rechallenge Outcomes

Treatment-related considerations for affected patients include the time to onset of symptoms, which varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Discontinuation of the drug is recommended if severe symptoms develop, and most patients had relief of symptoms after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A subset of patients had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A comprehensive understanding of these risks is essential for safe prescribing and patient management (https://pubmed.ncbi.nlm.nih.gov/41488140/). The timeline between exposure and documented harm can vary widely. The time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Additionally, the risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Once disease develops, a patient's activities of daily living are significantly compromised (https://pubmed.ncbi.nlm.nih.gov/40434545/).

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how is it related to osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate drug used to treat osteoporosis. It has been linked to osteonecrosis of the jaw (ONJ), a condition where the jaw bone dies and fails to heal, often after dental procedures. The risk may increase with longer use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the symptoms and risk factors for medication-related osteonecrosis of the jaw?

Symptoms include exposed bone in the mouth, pain, swelling, and infection. Risk factors include invasive dental procedures, cancer, chemotherapy, corticosteroids, poor oral hygiene, and pre-existing dental disease. The condition can significantly impair daily activities (https://pubmed.ncbi.nlm.nih.gov/40434545/).

How can the risk of ONJ be reduced in patients taking bisphosphonates?

Current guidelines recommend dental evaluation before starting high-potency antiresorptives. For patients needing invasive dental procedures, temporary discontinuation of bisphosphonate treatment may reduce ONJ risk. The optimal duration of therapy is not determined, but low-risk patients may consider stopping after 3-5 years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.